TY - JOUR
T1 - Chronic urticaria patients are interested in apps to monitor their disease activity and control
T2 - A UCARE CURICT analysis
AU - Cherrez-Ojeda, Ivan
AU - Vanegas, Emanuel
AU - Cherrez, Annia
AU - Felix, Miguel
AU - Weller, Karsten
AU - Magerl, Markus
AU - Maurer, Rasmus Robin
AU - Mata, Valeria L.
AU - Kasperska-Zajac, Alicja
AU - Sikora, Agnieszka
AU - Fomina, Daria
AU - Kovalkova, Elena
AU - Godse, Kiran
AU - Rao, Nimmagadda Dheeraj
AU - Khoshkhui, Maryam
AU - Rastgoo, Sahar
AU - Criado, Roberta F.J.
AU - Abuzakouk, Mohamed
AU - Grandon, Deepa
AU - Van Doorn, Martijn B.A.
AU - Rodrigues Valle, Solange Oliveira
AU - De Souza Lima, Eduardo Magalhães
AU - Thomsen, Simon Francis
AU - Ramón, German D.
AU - Matos Benavides, Edgar E.
AU - Bauer, Andrea
AU - Giménez-Arnau, Ana M.
AU - Kocatürk, Emek
AU - Guillet, Carole
AU - Larco, Jose Ignacio
AU - Zhao, Zuo Tao
AU - Makris, Michael
AU - Ritchie, Carla
AU - Xepapadaki, Paraskevi
AU - Ensina, Luis Felipe
AU - Cherrez, Sofia
AU - Maurer, Marcus
N1 - Publisher Copyright:
© 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
PY - 2021/12
Y1 - 2021/12
N2 - Background: Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self-evaluate their disease activity and control. Yet, recently Antó et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the chronic urticaria information and communication technologies (CURICT) study. Methods: The methodology for CURICT has been reported. Briefly, a 23-item questionnaire was completed by 1841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria-related purposes. Results: As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria (CIndU) [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ∼1/10 were not. Patients with both urticaria types versus those with CSU only (odds ratio [OR], 1.36 [1.03–1.79]) and females versus males (OR [95% CI], 1.47 [1.17–1.85]) were more likely to be very to extremely interested in an app to assess disease control. Conclusions: Overall, half of the patients with CU were very to extremely interested in using an app to assess their disease activity and control. Development of well-designed apps, specific to disease types (CSU, CIndU, CSU + CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research.
AB - Background: Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self-evaluate their disease activity and control. Yet, recently Antó et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the chronic urticaria information and communication technologies (CURICT) study. Methods: The methodology for CURICT has been reported. Briefly, a 23-item questionnaire was completed by 1841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria-related purposes. Results: As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria (CIndU) [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ∼1/10 were not. Patients with both urticaria types versus those with CSU only (odds ratio [OR], 1.36 [1.03–1.79]) and females versus males (OR [95% CI], 1.47 [1.17–1.85]) were more likely to be very to extremely interested in an app to assess disease control. Conclusions: Overall, half of the patients with CU were very to extremely interested in using an app to assess their disease activity and control. Development of well-designed apps, specific to disease types (CSU, CIndU, CSU + CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research.
KW - UCARE
KW - apps
KW - chronische induzierbare urtikaria
KW - chronische spontane urtikaria
KW - chronische urtikaria
UR - https://www.scopus.com/pages/publications/85122005119
U2 - 10.1002/clt2.12089
DO - 10.1002/clt2.12089
M3 - Artículo
AN - SCOPUS:85122005119
SN - 2045-7022
VL - 11
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
IS - 10
M1 - e12089
ER -